Cytotoxicity of HexAbs on CLL patient specimens as determined by the MTS assay
| Patient ID . | CD20 expression . | Rituximab . | Rituximab +GAH . | Veltuzumab . | Veltuzumab+GAH . | 20-20 . | 22-20 . | 20-22 . |
|---|---|---|---|---|---|---|---|---|
| CLL021 | Low | 114 ± 6 | 120 ± 6 | 113 ± 12 | 103 ± 11 | 117 ± 2 | 118 ± 6 | 114 ± 4 |
| CLL022 | Low | 102 ± 5 | 107 ± 5 | 106 ± 1 | 102 ± 3 | 114 ± 1 | 113 ± 1 | 99 ± 2 |
| CLL030 | Low | 107 ± 2 | 105 ± 2 | 105 ± 3 | 105 ± 16 | 108 ± 3 | 115 ± 2 | 104 ± 3 |
| CLL037 | Low | 107 ± 5 | 102 ± 18 | 102 ± 8 | 90 ± 4 | 109 ± 4 | 99 ± 3 | 96 ± 6 |
| CLL078 | Moderate | 104 ± 1 | 98 ± 2 | 101 ± 3 | 93 ± 4 | 74 ± 5 | 76 ± 1 | 72 ± 2 |
| CLL113 | High | 101 ± 1 | 97 ± 4 | 92 ± 1 | 96 ± 3 | 45 ± 2 | 43 ± 3 | 39 ± 5 |
| CLL117 | Low | 107 ± 9 | 98 ± 7 | 98 ± 8 | 97 ± 1 | 101 ± 7 | 102 ± 5 | 84 ± 2 |
| CLL145 | Moderate | 100 ± 4 | 107 ± 3 | 106 ± 6 | 101 ± 9 | 84 ± 1 | 79 ± 1 | 73 ± 2 |
| Patient ID . | CD20 expression . | Rituximab . | Rituximab +GAH . | Veltuzumab . | Veltuzumab+GAH . | 20-20 . | 22-20 . | 20-22 . |
|---|---|---|---|---|---|---|---|---|
| CLL021 | Low | 114 ± 6 | 120 ± 6 | 113 ± 12 | 103 ± 11 | 117 ± 2 | 118 ± 6 | 114 ± 4 |
| CLL022 | Low | 102 ± 5 | 107 ± 5 | 106 ± 1 | 102 ± 3 | 114 ± 1 | 113 ± 1 | 99 ± 2 |
| CLL030 | Low | 107 ± 2 | 105 ± 2 | 105 ± 3 | 105 ± 16 | 108 ± 3 | 115 ± 2 | 104 ± 3 |
| CLL037 | Low | 107 ± 5 | 102 ± 18 | 102 ± 8 | 90 ± 4 | 109 ± 4 | 99 ± 3 | 96 ± 6 |
| CLL078 | Moderate | 104 ± 1 | 98 ± 2 | 101 ± 3 | 93 ± 4 | 74 ± 5 | 76 ± 1 | 72 ± 2 |
| CLL113 | High | 101 ± 1 | 97 ± 4 | 92 ± 1 | 96 ± 3 | 45 ± 2 | 43 ± 3 | 39 ± 5 |
| CLL117 | Low | 107 ± 9 | 98 ± 7 | 98 ± 8 | 97 ± 1 | 101 ± 7 | 102 ± 5 | 84 ± 2 |
| CLL145 | Moderate | 100 ± 4 | 107 ± 3 | 106 ± 6 | 101 ± 9 | 84 ± 1 | 79 ± 1 | 73 ± 2 |
Values shown are percentage of untreated controls. Cells were treated with each antibody at 10nM and, where indicated, GAH at 10 μg/mL. The CD20 expression levels of the CLL specimens were provided by Dr Rhona Stein (personal e-mail communication, May 13, 2010).
MTS indicates the viability assay using One Solution assay reagent; and GAH, goat anti–human secondary antibody used for cross linking.